FDA rejects AP Pharma nausea/vomiting drug; shares kicked in the gut
This article was originally published in Scrip
Executive Summary
AP Pharma revealed on 28 March it had received a complete response letter (CRL) from the US FDA for the firm's chemotherapy-induced nausea and vomiting (CINV) drug APF530 – sending shares of the specialty pharma plummeting as low as 52%, or 30 cents, in morning trading.